Gastrointestinal Cancers Session from the Pittsburgh Annual Oncology Symposium Experts and Evidence 2025
2025 Pittsburgh Annual Oncology Symposium: Experts and Evidence
TOPIC: Gastrointestinal Cancers
Activity snapshot
- Release Date: November 1, 2025
- Expiration Date: November 1, 2026
- Activity Price: Free
- Expected Duration: 30 Minutes
Learning objectives
Identify new developments in immunotherapy and precision medicine for early-stage colorectal cancer and cholangiocarcinoma.
Discuss highlights in gastrointestinal cancers from the 2025 ASCO Annual Meeting.
15 minutes | Immunotherapy in Early-stage Colorectal Cancer: A Shifting Paradigm
Frank Sinicrope
15 minutes | New Developments in Precision Medicine and Immunotherapy Management of Cholangiocarcinoma
Milind Javle
15 minutes | Highlights from the 2025 ASCO Annual Meeting
Janie Zhang
Frank Sinicrope, MD, FACP – Consultant: Hoffmann-La Roche, Guardant Health; Co-patent Holder: Mayo Foundation for Medical Education & Research and Ventana Medical Systems, Inc.
Milind Javle, MD – Consultant: AbbVie, Array, Astellas, AstraZeneca, Bayer, BeiGene, Biocartis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi, GSK, Halozyme, Helsinn, Incyte, Ipsen, Janssen
Janie Zhang, MD – Consultant: AstraZeneca.
Faculty